
Fadi Haddad/X
Mar 2, 2024, 18:48
Fadi Haddad: Out in NEJM rusfertide in Polycythemia vera
Fadi Haddad, Assistant Professor, Leukemia Department MD Anderson Cancer Center, Houston, shared a post on X/Twitter:
“Out in NEJM rusfertide in Polycythemia vera
Rusfertide = hepcidin mimetic
S/C weekly
N=59 in Phase 2 (Rusfertide=30, Placebo=29)
Ht control and absence of phlebotomy, 60% vs 17%
Improved symptoms with rusfertide”
Source: Fadi Haddad/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 19, 2025, 10:56
Feb 19, 2025, 10:50
Feb 19, 2025, 10:44
Feb 19, 2025, 10:26
Feb 19, 2025, 10:16
Feb 19, 2025, 10:12
Feb 19, 2025, 10:06